Kornimate/medical-research-clean huggingface dataset:
long term complaints after elective repair for small umbilical or epigastric hernias

Conditions: Ventral Hernia

Summary: the purpose of this study is to compare the long-term complaints after ventral hernia repair after insertion of different types of mesh compared with primary suture. also recurrence of hernia will be discussed.

the purpose of this study is to compare the long-term complaints after ventral hernia repair after insertion of different types of mesh compared with primary suture. based on a questionnaire selected patients will be invited to clinical examination for recurrence and more detailed interview.

Eligibility criteria:
inclusion criteria: * operated for ventral hernia from the year 2004 to the year 2009 exclusion criteria: * liver cirrhosis * pregnancy * combined hernia * operation for ventral hernia and other operation * laparoscopic operation * acute operation * recurrence of hernia

Keywords: ventralex ventral hernia
comparing two training methods for opioid wizard

Conditions: Opioid-use Disorder; Opioid Dependence; Attitude of Health Personnel

Summary: the prevalence of opioid use disorder (oud) and opioid-related deaths has risen dramatically in recent years. effective treatments, including medications for opioid use disorder (mouds; e.g., buprenorphine-naloxone and methadone) are under-utilized. there are few evidence-based interventions for changing attitudes toward opioid use disorder (oud) in the general public and especially among healthcare clinicians. this study proposed an innovative intervention to change attitudes of primary care clinicians (pccs) toward persons with oud. study participants were stratified into one of two online learning courses: the intervention training was compared with an attention-control training.

primary care offers an ideal setting in which to treat oud; however, few clinicians are waivered to prescribe buprenorphine and of those who are waivered, less than one-third do prescribe. one potential barrier to increasing access to mouds are primary care clinician (pcc) attitudes towards people with oud. this study used a randomized controlled trial design to examine a novel intervention to change attitudes towards people with oud among pccs. pccs in clinics randomized to the intervention in compute 2.0 (pccs in 15 of the 30 clinics randomized in the parent study) were randomized 1:1 to the intervention or comparison training, stratified by clinic and waiver status. training was conducted via mylearning, an online learning software. all pccs were asked to complete a brief training (25-35 minutes for both trainings) on the shared decision-making tool (sdm) called the opioid wizard, which alerts pccs to screen, diagnose, and treat people with oud. pccs in the intervention arm heard patient narratives designed to shift attitudes about patients with oud. pccs in the comparison training had training on using the sdm tool. the pccs were asked to complete a survey of attitudes and intentions to get waivered to prescribe buprenorphine immediately following the online training. use of the cds was monitored in both groups for 6 months.

Eligibility criteria:
inclusion criteria: * primary care clinician: had to be a family physician, general internist, adult-care non-obstetric nurse practitioner, or a physician assistant * had to practice at a study-eligible primary care clinic already involved in the main study intervention arm exclusion criteria: pccs were ineligible to participate if they had fewer than 5 eligible patient encounters between sep 2020 and feb 2021.
proteome- and methylation profiles in oropharyngeal cancer

Conditions: Oropharynx Cancer

Summary: this clinical study aims to evaluate proteome- and methylation profiles in saliva in patients with oropharyngeal cancers


Eligibility criteria:
cancer group: inclusion criteria: * written informed consent * verified oropharyngeal squamous cell carcinoma exclusion criteria: * other active cancer * uncontrolled comorbidity * unable to give informed consent control group: inclusion criteria: * written informed consent * normal ent examination exclusion criteria: * active cancer * uncontrolled comorbidity * unable to give informed consent
alveolar ridge augmentation with curcumin combined with xenograft

Conditions: Horizontal Alveolar Bone Loss

Summary: a study was performed to investigate the effect of curcumin on the osteogenic differentiation of human periodontal ligament stem cells (hpdlscs) and its underlying potential mechanism. the results was that curcumin at an appropriate concentration had no cytotoxicity and could promote osteogenic differentiation of the hpdlscs

patients will be selected from the outpatient clinic of oral medicine, periodontology and oral diagnosis department, faculty of dentistry, ain shams university. the purpose of the study will be explained to all patients and an informed consent will be signed before the conduction of the study .the faculty research ethics committee will review the proposal. the study will be conducted in the form of patient intervention comparative outcome (pico) question (patient "p", intervention "i", comparative "c", outcome "o"). (stone 2002) "p": patient in the study will have enough alveolar ridge height ,suffering from missing from 1 to 3 upper maxillary anterior and /or premolar with insufficient alveolar ridge buccolingual (bl) width that interfere with conventional straight forward implant placement. the minimum bl width included in the study will be 4 mm. "i": ridge splitting with interposition grafting with curcumin and particulate xenograft grafting. "c":alveolar ridge splitting with interposition grafting with use of particulate xenograft alone without curcumin . "o":clinical and radiographic outcome.

Eligibility criteria:
inclusion criteria: * male and female with age range 25-45 years. * patient with enough alveolar ridge height, suffering from missing single or multiple maxillary anterior and /or premolar with insufficient alveolar ridge buccolingual (bl) width that interfere with conventional straight forward implant placement. the minimum bl width included in the study will be 4-5 mm to facilitate ridge splitting and expansion. * systemically free from any diseases as evidenced by burket's oral medicine health history questionnaire. * patient available during follow up periods. exclusion criteria: * smokers. * pregnant and breast feeding females. * patient unwilling to comply to oral hygienic instructions. * patients under any medication or medical condition that affect the bone quality. * vulnerable groups. (e.g decisions impaired individual).

Keywords: curcumin xenograft piezoelectric alveolar ridge splitting
glucobay m observation study for efficacy and safety in treatment of type-2 diabetes patients

Conditions: Type 2 Diabetes

Summary: an observational and multicenter study to assess the effectiveness and safety of glucobay®- m under daily life treatment of type-2 diabetes patients.the study objectives are to investigate the effectiveness and safety of glucobay® -m on blood glucose and patients body - weight. glucobay®- m is taken 1-3 times daily. all patients with type 2 diabetes mellitus, where investigator feels that addition of glucobay®-m would be beneficial to patients will be included in non- interventional study. the routine investigation suggested by the attending physician will be done in diabetic patients. no additional investigation will be done for the study purpose. the uncontrolled diabetic patient on existing treatment and prescribed glucobay®-m will be included in study after taking the informed consent. the patient will be asked to attend 2 follow up visit each after 6 weeks. all patients receiving at least one tablet will be included in the safety analysis.the study is planned to be carried out in 10000 patients from 320-350 trial sites in india.


Eligibility criteria:
inclusion criteria: * female and male patients ≥ 18 years of age with type 2 diabetes where investigator feels that addition of glucobay®-m would be beneficial to patients. * the diagnosis will be made based on the ada criteria by the attending physician. * patients will be defined as included in the study if they have a documented prescription of glucobay-m by the physician. * patients willing to provide signed \& dated informed consent. * patients willing to comply with study requirements. exclusion criteria: * according to the local product information

Keywords: diabetes mellitus type-2 acarbose metformin drug therapy, combination
impact of healthy diet on metabolic health in men and women

Conditions: Healthy Aging; Metabolic Syndrome; Diet, Healthy

Summary: the overall aim of the present research program is to determine how a healthy whole-diet approach impacts on cardiometabolic health in adults. with its interdisciplinary approach, the study depicts mechanisms behind disease progression and the impact of healthy dietary patterns on changes in markers of low-grade systemic inflammation together with the exploration of knowledge and attitudes about healthy diets. the study has a preventive character as it targets older adults (65+) without manifest disease.

this two arm randomized-controlled study includes the following groups: controls and healthy diet group. the study will particularly address the following aspects: * determine food literacy, perceived attitudes and barriers for the adoption of new dietary habits incorporating increased fruit and vegetable intake in adults. * explore the effects of a randomized controlled intervention promoting healthy dietary patterns (increased intakes of fruit and vegetable, whole-grain, nuts and low fat dairy products and replacing saturated with unsaturated fats and decreased red meat and salt consumption) for a period of 4 months on components of the metabolic syndrome, a large panel of pro- and anti-inflammatory biomarkers and metabolomic profile in adults. * assess the long-term adherence to healthy dietary patterns in adults. * provide support for behavioural change and evaluate participants' perception of this support.

Eligibility criteria:
inclusion criteria: * 65-70 years * not meeting 5 servings of fruit and vegetable per day * waist circumference \>80 cm (female) and \>88 (male) exclusion criteria: * movement disability * diabetes, cardiovascular disease, lung disease, overt disease
phase 2a, dose-ranging study with pf-05221304 in nonalcoholic fatty liver disease (nafld)

Conditions: Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis

Summary: phase 2a, dose-ranging study with pf-05221304 in nonalcoholic fatty liver disease (nafld)

a phase 2a, randomized, double-blind, placebo-controlled, dose-ranging, parallel group study to evaluate safety, tolerability, and pharmacodynamics of pf-05221304 administered daily for 16-weeks to adult subjects with nonalcoholic fatty liver disease

Eligibility criteria:
inclusion criteria: * body mass index \>= 25 kg/m2 * body weight \> 50 kg * liver fat (assessed via mri-pdff) \>= 8% * biopsy-proven nash - diagnosed in previous 24-months * presumed nash - per sponsor's definition * nafld with minimal inflammation/fibrosis * features of metabolic syndrome exclusion criteria: * alcohol-induced steatohepatitis or other forms of chronic liver disease * positive for hepatitis b, hepatitis c, or human deficiency virus * severe renal impairment * contraindications for mri

Keywords: pf-05221304 nafld nash features of metabolic syndrome dose-ranging study
study of intravenous ceftolozane/tazobactam compared to piperacillin/tazobactam in ventilator-associated pneumonia

Conditions: Ventilator-Associated Pneumonia (VAP)

Summary: this is a phase 3, multicenter, prospective, randomized, open-label, study to compare the safety and efficacy of intravenous (iv) ceftolozane/tazobactam with that of iv piperacillin/tazobactam in the treatment of ventilator-associated pneumonia (vap) in adult participants .


Eligibility criteria:
key inclusion criteria: * participant has received mechanical ventilation for \> 48 hours * acute physiology and chronic health evaluation (apache) ii score of 11-35 * presence of a new or progressive infiltrate on chest x-ray * presence of clinical criteria consistent with vap key exclusion criteria: * history of moderate or severe hypersensitivity reactions to beta-lactam antibiotics * known end stage renal disease or requirement for dialysis
ultra low doses of therapy with radiation applicated to covid-19

Conditions: Pneumonia, Viral; Cytokine Storm

Summary: the host response against the coronavirus 2 (sars-cov-2) appears to be mediated by a 'cytoquine storm' developing a systemic inflammatory mechanism and an acute respiratory distress syndrome (ards), in the form of a bilateral pneumonitis, requiring invasive mechanical ventilation (imv) in an important group of patients. in terms of preventing progression to the critical phase with the consequent need of admission to the intensive care units (icu), it has been recently proposed that this inflammatory cytoquine-mediated process can be safely treated by a single course of ultra-low radiotherapy (rt) dose \< 1 gy. the main purpose of the study was to analyze the efficacy of ultra low-dose pulmonary rt, as an anti-inflammatory intention in patients with sars-cov-2 pneumonia with a poor or no response to standard medical treatment and without imv.

the exceedingly high mortality rates of severe and critical covid-19 warrant the evaluation of novel therapies that could potentially mitigate the advanced disease manifestations. in this context, is proposes a prospective multicenter study. it will include 15 patients, to assess the feasibility and efficacy of low-dose lung irradiation in covid-19 pneumonia.

Eligibility criteria:
inclusion criteria: 1. age \> 18 years-old. 2. diagnosis of pneumonia due to covid-19 serologically proven by polymerase chain reaction (pcr) or highly suspected to be covid-related. 3. charlson comorbidity index (cci) less than 6 score. 4. poor or no response to standard medical treatment, based on: \*% sat02 \<93% * oxygen therapy escalation (understanding from less to more need for support: nasal cannula-nc-; ventimask -vmk- and vmk with reservoir) * pa02 / fi02 (blood gas analysis) \<300 mmhg * 1 or more inflammatory and immunological analytical parameters such as lymphocytes, il-6, d-dimer, ferritin, ldh, c reactive protein (crp) and fibrinogen with values above the normal range, except lymphocytes. * radiological impairment defined as worsening of tss throughout admission or score at admission: tss\> 5 by a diagnostic baseline ct scan. 5. eastern cooperative oncology group (ecog) status \< or = 3 6. life expectancy (le)\> 1 month at hospital admission for covid-19 7. no previous thoracic rt (relative-individualization criteria) or chemotherapy (chemoinduced pulmonary toxicity, eg bleomycin). 8. verbal information on the procedure, objective and secondary effects, acceptance and signing of informed consent by the patient or legal guardian. exclusion criteria: * failure to meet the inclusion criteria. * any uncontrolled intercurrent illness that would put the patient at greater risk or limit compliance with study requirements in the opinion of the investigator. * patients admitted in icu. * refusal of treatment after verbal information.

Keywords: low dose radiotherapy covid19 pneumonia anti-inflammatory effects acute respiratory distress syndrome (ards)
the effects of weight reduction in iga nephropathy

Conditions: Proteinuria

Summary: the study aims to explore the non-pharmacological treatment of iga nephropathy by weight reduction. the investigators hypothesized that benefits of weight loss may reduce proteinuria.

this is a prospective randomized study in adult iga nephropathy. the investigators enrolled 30 patients who have proteinuria exceeds 1 g per day with biopsy proven iga nephropathy. the experimental arm recieves the non-pharmacological treatment, weight reduction protocol. all patients in this arm must be reduce their body weight in 3-5 % from baseline as protocol. another arm is control group which recieves standard treatment of iga nephropathy including aceis/arbs for blood pressure control (target \< 130/80 mmhg). the primary outcome is proteinuria level. the secondary outcome is cytokines and inflammatory markers level including interleukin-6, resistin, adiponectin, leptin and monocyte chemoattractant protein-1.

Eligibility criteria:
inclusion criteria: * biopsy-proven iga nephropathy * body mass index more than 23 kg/m2 * 24 hours urine protein more than 1 g * estimated gfr more than 20 ml/min exclusion criteria: * pregnancy and lactation * rapidly renal function decline * crescent formation in renal biopsy more than 10%
beam for weight loss - a pilot study

Conditions: Obesity and Obesity-related Medical Conditions

Summary: bariatric endoscopic antral myotomy (beam) is a novel endoscopic technique which is performed using a gastroscope under general anesthesia. it involves cutting the muscle fibers at the gastric antrum, thereby weakening the antral pump, delaying gastric emptying and inducing satiety. early reports had shown that this technique can produce significant weight loss. furthermore, this technique has the potential benefits of lower risks, improved durability and allows subsequent mucosal assessment of stomach, which is important in asia countries with higher prevalence of gastric intestinal metaplasia or gastric cancers. given that this novel endoscopic technique has not been widely adopted for treatment of obesity, this pilot study aims to investigate the efficacy and safety of beam in obese patients who are eligible for endoscopic bariatric therapies.


Eligibility criteria:
inclusion criteria: * bmi equal or more than 30kg/m2 (27.5kg/m2 for chinese or south asian) to 40kg/m2, or bmi equal or more than 40kg/m2 and patient is either high risk for surgery or unwilling to undergo surgery, and * failed standard obesity therapy of diet, exercise, behavior modification, and pharmacologic agents either alone or in combination exclusion criteria: * previous upper gi surgery (e.g. bariatric surgery, anti-reflux surgery; gastrectomy; esophageal surgery) * gastroparesis * active smoking * an ongoing or a history of treatment with opioids in the last 12 months prior to enrollment * previous pyloromyotomy or pyloroplasty * gastrointestinal obstruction * use of any medication that may interfere with weight loss or gastric emptying * severe coagulopathy * esophageal or gastric varices and/or portal hypertensive gastropathy * underlying uncontrolled endocrine problem that leads to obesity. (e.g. hypothyroidism, cushing syndrome, eating disorder etc.) * any inflammatory disease of the gastrointestinal tract (including but not limited to severe (la grade c or d) esophagitis, active gastric ulceration, active duodenal ulceration, or specific inflammation such as crohn's disease) * malignancy * pregnant or breast feeding * patients not fit for general anesthesia * asa grade iv or v * mental or psychiatric disorder; drug or alcohol addiction * other cases deemed by the examining physician as unsuitable for safe treatment * refusal to participate
resting energy expenditure in patients with cystic fibrosis: a pilot study

Conditions: Cystic Fibrosis

Summary: cystic fibrosis is an inherited disorder that causes severe damage to the lungs, digestive system, and other organs in the body. individuals with cystic fibrosis often have poor weight gain and growth that can negatively impact health further by worsening lung function. additionally, persons with the disease typically need more than the usual calories on a daily basis. most institutions estimate these patients' caloric needs using weight, age, and sex based mathematical formulae. however, numerous studies show that use of these formulae often yields inaccurate caloric values. use of indirect calorimetry may give more accurate estimates of caloric needs in patients with cystic fibrosis. the aim of our study is to assess the accuracy of caloric estimates generated using one such widely used mathematical formula, the harris-benedict equation, and to compare this calorie value with that obtained from indirect calorimetry testing in pediatric and adult patients with cystic fibrosis. study investigators will use the newly calculated caloric requirements in dietary counseling. changes in weight and lung function after 3 months will be compared to participants' historical changes.


Eligibility criteria:
inclusion criteria: * patients with cystic fibrosis who are equal to or older than six years of age presenting to west virginia university-charleston cystic fibrosis center for their regularly scheduled appointments/check-ups. * patients at the cystic fibrosis center for at least 12 months. exclusion criteria: * patients with cystic fibrosis who are younger than 6 years of age. * patients without cystic fibrosis. * patients currently pregnant. * cystic fibrosis patients with significant disease exacerbation (such as needing oral steroids or antibiotics, hospital admission within 30 days) or patients who currently having the flu or a serious upper respiratory infection.

Keywords: cystic fibrosis
evaluation of the efficacy, safety and toleration of ct327 ointment in patients with psoriasis vulgaris

Conditions: Psoriasis Vulgaris

Summary: the purpose of this study is to evaluate the effectiveness of 3 dose strengths of ct327 ointment (0.05%, 0.1% and 0.05% w/w) compared to a placebo, when applied twice daily for up to 8 weeks, to the psoriatic plaques of patients with psoriasis vulgaris.


Eligibility criteria:
inclusion criteria: * male and female subjects aged at least 18 years. * stable psoriasis vulgaris exclusion criteria: * subjects with guttate, erythrodermic, exfoliative or pustular psoriasis.

Keywords: psoriasis vulgaris topical ointment
psycho-esthetic impact of tattoo technology as part of mammary reconstruction after surgery against breast cancer

Conditions: Breast Cancer; Right or Left Breast Mammary Reconstruction; Malignant Neoplasm Reconstruction by Tattoo of Areola of Female Breast

Summary: mammary reconstruction replaces total skin transplant, which may causing patient discomfort. it is a simple, painless and reproductible technology that avoids consequences and complications related to transplant. tattoo helps patients to return faster to the normal life and close more easily the cancer episode. the study purpose is to measure the patient's esthetic satisfaction degree on 1year areola tattoo realized following standard care.

tattoo is realized as standard car as part of mammary reconstruction after surgery of patient suffering from breast cancer. we try to measured : * tattooed patient's satisfaction degree with qualitative questionnaire using four level satisfaction scale (very satisfied, satisfied, dissatisfied, very dissatisfied) * evaluate from patient and jury, the tall, form, color and areola position defects * evaluate professional jury's satisfaction degree regarding this areola tattoo technology, with the same patient criteria

Eligibility criteria:
inclusion criteria: * technology areola tattoo realized as part of 1 breast mammary reconstruction following an operated breast cancer exclusion criteria: * two breasts operated patient * surgical reconstruction